PriceTargets.com logo

Aptinyx - APTX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.10 As of 12/29/2023 04:59 PM ET
▲ +0.0029 (3.11%)
Get New Aptinyx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APTX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Aptinyx in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.10.

This chart shows the closing price for APTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Aptinyx. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/7/2023HC WainwrightDowngradeBuy ➝ NeutralLow
3/1/2023SVB LeerinkReiterated RatingOutperform ➝ Market Perform$0.50Low
3/1/2023SVB SecuritiesDowngradeOutperform ➝ Market PerformLow
8/26/2022HC WainwrightLower TargetBuy$2.00 ➝ $1.00Low
8/15/2022CowenDowngradeMarket PerformLow
8/15/2022CowenDowngradeOutperform ➝ Market PerformLow
8/15/2022Truist FinancialDowngradeBuy ➝ HoldLow
8/15/2022BMO Capital MarketsLower TargetOutperform$6.00 ➝ $2.00Low
8/12/2022Piper SandlerDowngradeOverweight ➝ Neutral$6.00 ➝ $2.00Low
8/5/2022SVB LeerinkLower TargetOutperform$4.00 ➝ $3.00Low
5/18/2022Piper SandlerLower TargetOverweight$10.00 ➝ $6.00High
4/21/2022SVB LeerinkLower TargetOutperform$10.00 ➝ $4.00Low
4/14/2022HC WainwrightLower TargetBuy$8.00 ➝ $2.00Low
4/8/2022BMO Capital MarketsLower Target$12.00 ➝ $6.00High
4/8/2022Truist FinancialLower TargetBuy$12.00 ➝ $5.00High
4/8/2022Cantor FitzgeraldLower TargetOverweight$11.00 ➝ $5.00High
4/7/2022William BlairDowngradeOutperform ➝ Market PerformHigh
12/20/2021SVB LeerinkLower TargetOutperform$12.00 ➝ $10.00High
11/15/2021SVB LeerinkReiterated RatingBuyHigh
11/10/2021Cantor FitzgeraldReiterated RatingOverweightHigh
4/9/2021HC WainwrightReiterated RatingBuy$8.00High
1/29/2021JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightMedium
11/19/2020HC WainwrightBoost TargetPositive ➝ Buy$7.00 ➝ $8.00High
11/13/2020SVB LeerinkLower TargetOutperform$14.00 ➝ $12.00High
10/28/2020Cantor FitzgeraldBoost TargetOverweight$9.00 ➝ $12.00High
10/27/2020Piper SandlerInitiated CoverageOverweight$10.00Low
10/21/2020CowenReiterated RatingBuyMedium
10/20/2020SVB LeerinkBoost TargetOutperform$12.00 ➝ $14.00Low
10/14/2020JPMorgan Chase & Co.Initiated CoverageNeutralMedium
10/1/2020William BlairReiterated RatingBuyLow
8/14/2020BMO Capital MarketsReiterated RatingBuy$13.00Medium
7/1/2020SunTrust BanksInitiated CoverageBuy$15.00High
6/18/2020HC WainwrightReiterated RatingBuy$7.00High
5/7/2020William BlairInitiated CoverageOutperformMedium
4/29/2020HC WainwrightInitiated CoverageBuy$7.00High
11/14/2019CowenReiterated RatingBuyHigh
9/12/2019WedbushInitiated CoverageOutperform$7.00High
8/13/2019JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
6/20/2019SVB LeerinkInitiated CoverageOutperform ➝ Outperform$12.00High
6/10/2019CowenReiterated RatingBuyHigh
4/30/2019Cantor FitzgeraldReiterated RatingBuyLow
(Data available from 4/20/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/20/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Aptinyx logo
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
Read More

Today's Range

Now: $0.10
Low: $0.09
High: $0.10

50 Day Range

MA: $0.08
Low: $0.06
High: $0.10

52 Week Range

Now: $0.10
Low: $0.01
High: $0.72

Volume

231,100 shs

Average Volume

1,317,051 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Aptinyx?

The following sell-side analysts have issued research reports on Aptinyx in the last year:
View the latest analyst ratings for APTX.

What is the current price target for Aptinyx?

0 Wall Street analysts have set twelve-month price targets for Aptinyx in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Aptinyx in the next year.
View the latest price targets for APTX.

What is the current consensus analyst rating for Aptinyx?

Aptinyx currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for APTX.

What other companies compete with Aptinyx?

Other companies that are similar to Aptinyx include Context Therapeutics, Grifols, LAVA Therapeutics, Mainz Biomed and NLS Pharmaceutics. Learn More about companies similar to Aptinyx.

How do I contact Aptinyx's investor relations team?

Aptinyx's physical mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The company's listed phone number is (847) 871-0377 and its investor relations email address is [email protected]. The official website for Aptinyx is www.aptinyx.com. Learn More about contacing Aptinyx investor relations.